Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Puebla CP 72570, México.
Pharm Pat Anal. 2020 Sep;9(5):149-154. doi: 10.4155/ppa-2020-0017. Epub 2020 Sep 22.
PD-1 and CTLA-4 are checkpoint inhibitors of the immune response in cancer, making them the target molecules for the development of therapeutic antibodies. US2019161548 patent describes a bispecific antibody capable of specifically binding to PD-1 and CTLA-4 that induced the proliferation and activation of CD8 cells, as well as the expression of induclble co-stimulator in CD4 T cells. Clinical trials to evaluate safety, dose-limiting toxicities and maximum tolerated/administered dose are still in the patient recruitment phase, but it will be of great interest to the scientific and medical community to know if the first bispecific anti-PD-1/CLTA-4 antibody, exceeds expectations and exceeds action of the combination of nivolumab and epilimumab in the treatment of cancer.
PD-1 和 CTLA-4 是癌症免疫反应的检查点抑制剂，这使得它们成为治疗性抗体开发的靶分子。美国专利第 2019161548 号描述了一种能够特异性结合 PD-1 和 CTLA-4 的双特异性抗体，该抗体能够诱导 CD8 细胞的增殖和激活，以及 CD4 T 细胞中诱导共刺激分子的表达。评估安全性、剂量限制性毒性和最大耐受/给药剂量的临床试验仍处于患者招募阶段，但了解首个双特异性抗 PD-1/CLTA-4 抗体是否超出预期，以及是否超过纳武单抗和伊匹单抗联合治疗癌症的效果，将引起科学界和医学界的极大兴趣。
